Previous 10 | Next 10 |
Key Highlights: North American sales up by 95% YoY in Q3 FY20 Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to $475K. In the USA, ...
Immuron’s (NASDAQ: IMRN ) CEO Gary S. Jacob has offered his resignation as CEO and member of the Board, in response to the COVID-19 pandemic. More news on: Immuron Limited, Healthcare stocks news, Read more ...
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The World is in the midst of an unprecedented health crisis as a result of the COVI...
Key Highlights: Wuhan coronavirus outbreak expanding to global health emergency Outbreak while viral in nature highlights the role of global travel leading to respiratory and gastrointestinal infections Increased global travel over the past decade to sites endemic for gastrointesti...
Key Highlights: Strong continued growth of Travelan® sales reported in all markets North American Travelan® sales up by 98% YoY in the first half of FY20 Immuron achieved 55% YoY growth for the first half of FY20, with worldwide sales reaching AU $1.68M US Travelan®...
MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that CEO Dr. Gary ...
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD) Phase 3 clinical trial of IMM-124E to prevent TD planned for 2020 Previous clinical trial data on IMM-124E from earlier studies prov...
MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...
Immuron (NASDAQ: IMRN ) is up 17% premarket on announcing sales results for its OTC gastrointestinal and digestive health supplement Travelan, for Q1 2020 ended September 30, 2019. More news on: Immuron Limited, Healthcare stocks news, Stocks on the move, Read more ...
Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUD Q1 US Travelan® sales increased by +81% YoY to $232K AUD Global Immuron sales continued an upward trend in Q1 with a +54% YoY sales increase, reaching $741K AUD In Australi...
News, Short Squeeze, Breakout and More Instantly...
Sales Highlights: MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Travelan ® , an over-the-counter immune ...
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug A...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed a...